Masunori Kajikawa is a president and CEO of Rebirthel. He majored in organic synthesis chemistry at the Faculty of Engineering, Yokohama National University, and in medicine at the Research Institute of Environmental Medicine, Nagoya University. He started his career in a reagent and diagnostic agent manufacturing company. He was engaged in sales, pharmaceutical development, and research & development. In 2005, he co-founded ACT Gen, Inc. with Professor Toshio Kitamura, the Institute of Medical Science, University of Tokyo. He served as the executive officer of the R&D dep. and later CEO. In 2013, ACT Gen was absorbed and merged by Medical & Biological Laboratories (MBL), therefore he changed his position to a director of the corporate planning department. Afterward, he transferred to MBL International Corporation (USA) and served as the vice president. In 2021, he joined Rebirthel hoping to contribute to the healthcare business.